rituximab-hyaluronidase (Rx)

Brand and Other Names:Rituxan Hycela
  • Print

Dosing & Uses


Dosage Forms & Strengths


injectable solution

  • (120mg/2,000 units)/mL
  • Ready-to-use SC solution contains rituximab and hyaluronidase human

Follicular Lymphoma

All patients must receive at least 1 full dose of rituximab IV infusion before starting rituximab/hyaluronidase SC

Relapse or refractory follicular lymphoma

  • Indicated for relapsed or refractory follicular lymphoma (FL) as a single agent
  • Rituximab 1,400/hyaluronidase 23,400 units SC qWeek for 3 or 7 weeks following a full dose of rituximab IV at Week 1 (ie, 4 or 8 weeks total)
  • Retreatment relapse/refractory FL
    • Rituximab 1,400/hyaluronidase 23,400 units SC qWeek for 3 weeks following a full dose of a rituximab by IV infusion at Week 1 (ie, 4 weeks in total)

Previously untreated FL

  • Indicated for previously untreated FL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy
  • Rituximab 1,400/hyaluronidase 23,400 units SC on day 1 of a 21-day cycle in cycles 2-8, for up to 7 cycles, following a full IV rituximab dose on Day 1 of cycle 1 of chemotherapy (ie, up to 8 cycles in total)
  • Maintenance after complete or partial response
    • Single agent maintenance: Rituximab 1,400/hyaluronidase 23,400 SC q8Weeks x 12 doses
    • Initiate 8 weeks after complete or partial response to rituximab in combination with chemotherapy

Nonprogressing FL

  • Indicated for nonprogressing (eg, stable disease) FL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
  • Following completion of 6-8 cycles of CVP chemotherapy and a full dose of a rituximab by IV infusion at Week 1, rituximab 1,400 mg/hyaluronidase 23,400 units SC qWeek for 3 weeks (ie, 4 weeks in total) at 6-month intervals for maximum of 16 doses

Diffuse Large B-Cell Lymphoma

Indicated for previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens

Rituximab 1,400 mg/hyaluronidase 23,400 on Day 1 of cycles 2-8 in combination with CHOP for up to 7 cycles, following a full IV rituximab dose (Day 1, cycle 1) of CHOP (up to 6-8 cycles)

Chronic Lymphocytic Leukemia

Indicated, in combination with fludarabine and cyclophosphamide (FC), for treatment of adults with previously untreated and previously treated CLL

Rituximab 1,600 mg/hyaluronidase 26,800 units SC on Day 1 of a 28-day cycle in cycles 2-6 (in combination with FC) for a total of 5 cycles, following a full IV rituximab dose (Day 1 of cycle 1) of FC (ie, 6 cycles in total)

Dosing Considerations

Initiate treatment only after patients have received at least 1 full dose of rituximab IV infusion

Not indicated for nonmalignant conditions

Safety and efficacy not established



Interaction Checker

and rituximab-hyaluronidase

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Adverse Effects

            Percentages are for all grades of toxicity unless otherwise noted

            >10% (FL)

            Neutropenia (32%)

            Nausea (31%)

            Constipation (25%)

            Cough (23%)

            Fatigue (20%)

            Diarrhea (18%)

            Asthenia (17%)

            Pyrexia (15%)

            Anemia (15%)

            Abdominal pain (14%)

            Vomiting (14%)

            Alopecia (14%)

            Paresthesia (16%)

            Injection site erythema (13%)

            Arthralgia (13%)

            Peripheral neuropathy (12%)

            Dyspnea (11%)

            Pneumonia (11%)

            >10% (DLBCL)

            Neutropenia (31%)

            lopecia (24%)

            Anemia (23%)

            Nausea (22%)

            Fatigue (19%)

            Constipation (15%)

            Diarrhea (14%)

            Febrile neutropenia (14%)

            Decreased neutrophil count (14%)

            Pyrexia (13%)

            Peripheral neuropathy (12%)

            Cough (11%)

            Asthenia (11%)

            Vomiting (11%)

            >10% (CLL)

            Neutropenia (65%)

            Nausea (38%)

            Pyrexia (32%)

            Injection site erythema (26%)

            Thrombocytopenia (24%)

            Vomiting (21%)

            Leukopenia (19%)

            Injection site pain (16%)

            Erythema (15%)

            Anemia (13%)

            Chills (13%)

            Cough (13%)

            Upper respiratory tract infection (13%)

            Rash (12%)

            Diarrhea (12%)

            Fatigue (11%)

            Febrile neutropenia (11%)

            1-10% (FL)

            Bone pain (10%)

            Extremity pain (10%)

            Pruritus (10%)

            Rash (10%)

            Erythema (9%)

            Back pain (9%)

            Oropharyngeal pain (9%)

            Insomnia (9%)

            Dyspepsia (8%)

            Chills (8%)

            Injection site pain (8%)

            Chills (8%)

            Bronchitis (8%)

            Urinary tract infection (8%)

            Muscle spasms (8%)

            Myalgia (8%)

            Sinusitis (7%)

            Dizziness (7%)

            Insomnia (7%)

            Stomatitis (6%)

            Hypertension (6%)

            Conjunctivitis (5%)

            Upper abdominal pain (5%)

            Peripheral edema (5%)

            Mucosal inflammation (5%)

            Influenza (4%)

            Influenza-like illness (3%)

            Peripheral neuropathy, Grade 3-4 (2%)

            Diarrhea, Grade 3-4 (2%)

            Asthenia, Grade 3-4 (1%)

            Chest pain, Grade 3-4 (1%)

            Dyspnea, Grade 3-4 (1%)

            Hypertension, Grade 3-4 (1%)

            1-10% (DLBCL)

            Paresthesia (9%)

            Mucosal inflammation (8%)

            Peripheral edema (8%)

            Decreased weight (8%)

            Decreased appetite (8%)

            Abdominal pain (7%)

            Pneumonia (7%)

            Leukopenia (7%)

            Decreased WBC count (7%)

            Insomnia (7%)

            Stomatitis (6%)

            Headache (6%)

            Dyspnea (6%)

            Dyspepsia (5%)

            Lymphopenia (5%)

            Decreased lymphocyte count (5%)

            1-10% (CLL)

            Abdominal pain (9%)

            Arthralgia (9%)

            Constipation (8%)

            Asthenia (8%)

            Respiratory tract infection (8%)

            Pruritus (8%)

            Bronchitis (7%)

            Extremity pain (7%)

            Headache (7%)

            Bone pain (6%)

            Oropharyngeal pain (6%)

            Dyspnea (4%)

            Urinary tract infection (2%)

            Pneumonia (2%)

            Insomnia (1%)

            Hypotension (1%)

            Postmarketing Reports

            Skin: Severe mucocutaneous reactions, pyoderma gangrenosum (including genital presentation)



            Black Box Warnings

            Severe mucocutaneous reactions

            • Severe, including fatal, mucocutaneous reactions reported including paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis
            • Discontinue drug if severe mucocutaneous reaction occurs

            Progressive multifocal leukoencephalopathy

            • Progressive multifocal leukoencephalopathy (PML), including fatal PML, reported

            Reactivation of hepatitis B

            • Reactivation of hepatitis B virus (HBV) infection reported, including deaths
            • Screen all patients for HBV infection before initiating drug by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc)
            • Consult with hepatitis experts regarding monitoring and use of HBV antiviral therapy when screening identifies patients at risk of HBV reactivation due to evidence of prior HBV infection
            • Monitor patients with evidence of prior HBV infection for clinical and laboratory signs of hepatitis B or HBV reactivation during therapy and for several months thereafter, since reactivations have occurred several months following completion of therapy
            • If HBV reactivation develops, discontinue drug immediately and start HBV treatment; also discontinue any chemotherapy until the HBV infection controlled/resolved
            • Because of insufficient data, no recommendation can be made regarding the resumption of the drug in patients who develop HBV reactivation hepatitis




            Tumor lysis syndrome (TLS) can occur within 12-24 hr after administration; administer aggressive IV hydration and antihyperuricemic therapy in patients at high risk for TLS; correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated

            Cardiac adverse reactions (eg, ventricular fibrillation, myocardial infarction, cardiogenic shock) may occur; discontinue treatment for serious or life-threatening cardiac arrhythmias; perform cardiac monitoring during and after all administrations for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina

            Severe, including fatal, renal toxicity can occur after administration; closely monitor for signs of renal failure and discontinue treatment in patients with a rising serum creatinine or oliguria

            Abdominal pain, bowel obstruction, and bowel perforation can occur in patients receiving rituximab-containing products, in combination with chemotherapy; in postmarketing reports, the mean time to documented gastrointestinal perforation was 6 days; evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur

            Safety of immunization with live viral vaccines following rituximab-containing chemotherapy has not been studied, and vaccination with live virus vaccines is not recommended before or during treatment

            Based on human data, rituximab-containing products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in utero (see Pregnancy)


            • Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of rituximab
            • Infections reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure)
            • New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella-zoster virus, West Nile virus, and hepatitis B and C viruses
            • Discontinue treatment for serious infections and institute appropriate anti-infective therapy


            • Rituximab-containing products are associated with hypersensitivity and other administration reactions (eg, cytokine release syndrome, TLS, anaphylactic reactions)
            • Severe infusion-related reactions (eg, pulmonary events, fever, chills, rigors, hypotension, urticaria, angioedema) with fatal outcome reported with IV use of rituximab, with an onset ranging within 30-120 minutes after starting the first IV infusion
            • Cytokine release syndrome may occur within 1-2 hr of initiating infusion; severe cytokine release syndrome is characterized by severe dyspnea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema
            • Local cutaneous reactions may occur more than 24 hr after administration
            • During administration, interrupt treatment immediately when observing signs of a severe reaction, and initiate aggressive symptomatic treatment; closely monitor the following patients: those with preexisting cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (≥25,000/mm³ )
            • Premedicate patients with an antihistamine and acetaminophen prior to each administration; also consider glucocorticoids

            Pregnancy & Lactation


            Based on human data, rituximab can cause adverse developmental outcomes including B-cell lymphocytopenia in infants exposed to rituximab in utero

            There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage

            Verify pregnancy status in females of reproductive potential prior to initiating therapy

            Animal data

            • In animal reproduction studies, IV administration of a rituximab to pregnant cynomolgus monkeys during organogenesis caused lymphoid B-cell depletion in newborn offspring at doses resulting in 80% of the exposure (based on AUC) of those achieved following a dose of 2 g in humans
            • Reduced fetal weight and increased fetal lethality were observed following SC administration of hyaluronidase human in mice at a dose >2700 times higher than the human dose


            • Females of childbearing potential should use effective contraception during treatment and for 12 months following treatment


            There are no data on the presence of rituximab or hyaluronidase human in human milk, the effect on the breastfed infant, or the effect on milk production

            However, rituximab is detected in the milk of lactating cynomolgus monkeys, and IgG is present in human milk

            Advise a lactating woman not to breastfeed during treatment and for at least 6 months after last dose

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Monoclonal antibody targets CD20 antigen expressed on pre-B and mature B-lymphocytes’ surfaces

            Upon binding to CD20, mediates B-cell lysis

            Hyaluronidase human increases permeability of SC tissue by temporarily depolymerizing hyaluronan

            In doses administered, hyaluronidase human acts locally; effects of hyaluronidase human are reversible and permeability of SC tissue is restored within 24-48 hr


            Bioavailability: 0.646 (FL); 0.634 (CLL)

            Peak plasma concentration

            • FL: 237 mcg/mL (cycle 7); 156 mcg/mL (cycle 18)
            • CLL: 202 mcg/mL (cycle 6)

            Peak trough concentration

            • FL: 122.2 mcg/mL (cycle 7); 45.5 mcg/mL (cycle 18)
            • CLL: 97.5 mcg/mL (cycle 6)


            • FL: 3,779 mcg·d/mL (cycle 7); 5,000 mcg·d/mL (cycle 18)
            • CLL: 4088 mcg·d/mL (cycle 5)


            Vd (steady-state): 8.09 L (FL); 8.52 (CLL)


            Half-life: 34.1 days (FL); 32 days (CLL)

            Clearance: 0.18 L/day (FL); 0.204 (CLL)



            SC Preparation

            Solution for SC is ready to use

            Visually inspect solution for particulates; solution should appear as a clear-to-opalescent and colorless-to-yellowish liquid

            SC Administration

            Consider premedication (ie, acetaminophen, diphenhydramine, and/or glucocorticoids)

            Premedication with acetaminophen and diphenhydramine may attenuate infusion-related reactions

            Observe patients for 15 minutes after SC administration

            If administration is interrupted, administer at the same site or at a different site along the abdomen

            Avoid coadministering other SC medications at the same site

            Avoid injections into areas where skin appears red, bruised, tender, or hard

            Avoid injections in areas where there are moles or scars No data available on other injection sites

            SC injection rate

            • Inject SC in abdomen
            • 1,400 mg/23,400 IU/vial (1,400 mg rituximab and 23,400 Units hyaluronidase human): SC over ~5 minutes
            • 1,600 mg/26,800 IU/vial (1,600 mg rituximab and 26,800 Units hyaluronidase human): SC over ~7 minutes


            Unused vials: Refrigerate at 2-8°C (36-46°F)

            Solution for SC injection: Refrigerate at 2-8°C (36-46°F) up to 48 hr and subsequently for 8 hr at room temperature up to 30°C (86°F)

            Protect vials and solution from light





            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.